Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 41Terminated 21Recruiting 10Active not recruiting 8Withdrawn 4Unknown 4Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 12Hematologic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 5Urinary Bladder Neoplasms 4Leukemia, Myeloid, Acute 4Colorectal Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Myasthenia Gravis 3Multiple Myeloma 3Lung Neoplasms 3Kidney Neoplasms 3Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Heart Failure 2Glioma 2Glioblastoma 2Esophageal Neoplasms 2Diabetes Mellitus, Type 2 2

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × INDUSTRY × Leukemia, Myelomonocytic, Chronic × Clear all
NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Taiho Oncology, Inc.

Phase 2 Enrolling by invitation
332 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡